By using this single panel to analyze samples from two additional NSCLC patients, we found that we had successfully identified 95.5 and 96.2% of all CD45+ leukocytes in squamous cell carcinoma and adenocarcinoma, respectively (Supplementary Figures 25, 26). This evidence concerns the gene PTPRC and squamous cell carcinoma.